Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study-Reference-Cited by-同舟云学术

Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study

Published:2022-03-17 Issue:5 Volume:15 Page:1204-1214
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Boettcher Michael¹²^ORCID,Mikus Gerd³,Trenk Dietmar⁴,Düngen Hans‐Dirk⁵,Donath Frank⁶,Werner Nikos⁷,Karakas Mahir⁸,Besche Nina⁹,Schulz‐Burck Dominik¹⁰,Gerrits Mireille¹¹,Hung James¹²,Becker Corina¹^ORCID

Affiliation:

1. Clinical Pharmacology Bayer AG Wuppertal Germany

2. Graduate Physicist and Physician and Lecturer at the University of Applied Science at the RFH‐Cologne Cologne Germany

3. Department of Clinical Pharmacology and Pharmacoepidemiology University Hospital Heidelberg Heidelberg Germany

4. Department of Cardiology and Angiology II Section Clinical Pharmacology Heart Center University of Freiburg Bad Krozingen Germany

5. Department of Internal Medicine, Cardiology Charité – Universitätsmedizin Berlin Berlin Germany

6. SocraTec R&D GmbH Erfurt Germany

7. Heart Center Trier Krankenhaus der Barmherzigen Bruder Nordallee, Trier Germany

8. Department of Intensive Care Medicine University Medical Center Hamburg Eppendorf, Hamburg Germany

9. Chrestos Concept GmbH & Co. KG Essen Germany

10. Bayer AG, Research & Development Pharmaceuticals Wuppertal Germany

11. Merck Sharp & Dohme Corp a Subsidiary of Merck & Co., Inc. Kenilworth New Jersey USA

12. Clinical Operations Study Medical Experts Bayer SA São Paulo Brazil

Funder

Bayer

Merck Sharp and Dohme

Merck

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13238

Reference26 articles.

1. Global Public Health Burden of Heart Failure

2. The annual global economic burden of heart failure

3. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

4. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction

5. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat;Clinical Pharmacokinetics;2024-06

2. Economic evaluation of isosorbide mononitrate sustained-release capsules for the treatment of angina pectoris;Journal of Holistic Integrative Pharmacy;2024-03

3. Compound Danshen Dripping Pills combined with isosorbide mononitrate for angina pectoris: A systematic review and a Meta-analysis;Chinese Herbal Medicines;2024-03

4. New possibilities in pharmacotherapy for the heart failure with reduced ejection fraction treatment in patients with recent deterioration;Rational Pharmacotherapy in Cardiology;2024-02-06

5. Vericiguat for the treatment of heart failure with reduced ejection fraction;Expert Review of Cardiovascular Therapy;2023-03-13